Fluticasone Propionate And Salmeterol Powder
Product Images NDC 66993-584

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 66993-584). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Chemical structure of the active ingredient fluticasone propionate, showing the molecular arrangement with labeled atoms and bonds in a detailed skeletal formula.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Chemical structure diagram showing two distinct molecular structures likely representing the active ingredients fluticasone propionate and salmeterol from Fluticasone Propionate and Salmeterol DISKUS inhalation powder by Prasco Laboratories.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

Line graph showing the percentage change in FEV1 over 12 weeks and at the study endpoint for four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo. The graph tracks improvements starting from week 0, with Fluticasone propionate/salmeterol showing the highest increase, followed by the other active treatments, and placebo showing minimal change. Patient numbers at various time points are also listed below the graph.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

Line graph showing the % change in FEV1 over 12 hours from baseline on Day 1, comparing four treatments: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. The combined treatment shows the highest % improvement, followed by salmeterol alone, fluticasone alone, and placebo.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

This line graph depicts the percent change in FEV1 relative to Day 1 baseline over a 12-hour period. It compares four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo, with sample sizes ranging from 26 to 73. The y-axis represents percent change in FEV1, and the x-axis shows time in hours post-dose.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

A line graph showing the percent change in FEV1 (forced expiratory volume) over 24 weeks for Fluticasone propionate/salmeterol 250/50 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo. The graph includes baseline FEV1 values and sample sizes (N) for each group at different time points.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

A line graph comparing the percent change in FEV1 over time for three groups: Fluticasone propionate/salmeterol 250/50 mcg, Fluticasone propionate 250 mcg, and placebo. The x-axis represents days and weeks, and the y-axis shows percent change in FEV1. The graph includes sample sizes at various time points for each group.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

An illustration showing the parts of a Fluticasone Propionate and Salmeterol DISKUS inhalation device with 100 mcg/50 mcg strength powder. Labeled components include the outer case, mouthpiece, lever, thumb grip, and counter.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

An instructional illustration showing a person holding a Fluticasone Propionate and Salmeterol DISKUS inhaler device in their hands. The image emphasizes the gripping and sliding motion to operate the Diskus, indicated by a large arrow pointing horizontally. The Diskus is a powder inhalation device used for respiratory administration.*

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

Instructional image showing a person holding a DISKUS inhaler device. The person's thumb is pushing the lever or lever mechanism horizontally, as indicated by a large arrow, demonstrating how to activate or load the Fluticasone Propionate and Salmeterol DISKUS powder inhalation device for respiratory use.*

FDA Label Image

Ifu Figure D (Fp Sal Spl Graphic 11)

An illustration showing a woman holding and preparing to use a Fluticasone Propionate and Salmeterol DISKUS inhalation device. The image demonstrates proper handling of the respiratory powder inhaler by positioning it near the mouth for inhalation.*

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

An instructional illustration showing a woman using a Fluticasone Propionate and Salmeterol DISKUS inhaler by placing it to her mouth and preparing to inhale the powder medication for respiratory treatment.*

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

An instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler with an arrow indicating the direction to slide the device open for use. The diagram demonstrates how to prepare the DISKUS for inhalation.*

FDA Label Image

Ifu Figure G (Fp Sal Spl Graphic 14)

An illustration showing a woman using a water cup to rinse and spit into a sink. This likely depicts a step after inhalation with a respiratory powder device, emphasizing oral hygiene.*

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Fluticasone Propionate and Salmeterol DISKUS inhalation powder device shown with a label indicating 100 mcg/50 mcg strength. The image includes the dispenser and one round tablet marked with the number 5, representing the powder dose form for respiratory inhalation.*

FDA Label Image

Fluticasone Propionate-salmeterol Diskus 100-50 Mcg Carton (Fp Sal Spl Graphic 16)

Fluticasone Propionate and Salmeterol DISKUS Inhalation Powder 100 mcg/50 mcg packaging label showing a purple DISKUS device. The label indicates the product is for oral inhalation only, contains 60 blisters, and is manufactured by Prasco Laboratories. The label also displays the NDC number 66993-584-97.*

FDA Label Image

Fluticasone Propionate-salmeterol Diskus 250-50 Mcg Carton (Fp Sal Spl Graphic 17)

Label for Fluticasone Propionate and Salmeterol DISKUS Inhalation Powder 250 mcg/50 mcg by Prasco Laboratories. The label shows a purple DISKUS device and indicates it contains 1 foil strip of 60 blisters. It is a powder for oral inhalation only, with each blister containing 250 mcg fluticasone propionate and 50 mcg salmeterol.*

FDA Label Image

Fluticasone Propionate-salmeterol Diskus 500-50 Mcg Carton (Fp Sal Spl Graphic 18)

Fluticasone Propionate/Salmeterol DISKUS Inhalation Powder 500 mcg/50 mcg packaging label displaying the Prasco Laboratories logo. The label specifies oral inhalation use with 1 DISKUS device containing a foil strip of 60 blisters. The purple DISKUS device is shown prominently with dosage details on the center label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.